info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pharmacogenomics Market Research Report Information By Technology (Microarray, Sequencing, and Polymerase Chain Reaction), By Application (Oncology, Cardiology, and Neurological Disorders), By End User (Hospitals, Research Organizations and Academic Institutes) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) โ€“Market Forecast Till 2032


ID: MRFR/LS/0671-HCR | 90 Pages | Author: Kinjoll Dey| November 2024

Market Segmentation


Pharmacogenomics Market Technology Outlook (USD Billion, 2018-2032)




  • Microarray




  • Sequencing




  • Polymerase Chain Reaction




Pharmacogenomics Market Application Outlook (USD Billion, 2018-2032)




  • Oncology




  • Cardiology




  • Neurological Disorders




Pharmacogenomics Market End User Outlook (USD Billion, 2018-2032)




  • Hospitals




  • Research Organizations and Academic Institutes




Pharmacogenomics Market Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • US Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Canada Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes








  • Europe Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Germany Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • France Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • UK Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Italy Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Spain Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • China Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Japan Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • India Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Australia Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Middle East Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Africa Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes






    • Latin America Outlook (USD Billion, 2018-2032)




    • Pharmacogenomics Market by Technology




      • Microarray




      • Sequencing




      • Polymerase Chain Reaction






    • Pharmacogenomics Market by Application




      • Oncology




      • Cardiology




      • Neurological Disorders






    • Pharmacogenomics Market by End User




      • Hospitals




      • Research Organizations and Academic Institutes







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Pharmacogenomics Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Pharmacogenomics Market: Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Pharmacogenomics Market Size Estimation

Chapter 4. Pharmacogenomics Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Pharmacogenomics Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pharmacogenomics Market, by Technology

6.1 Introduction

6.2 Microarray

Market Estimates & Forecast, 2020-2025

6.3 Sequencing

Market Estimates & Forecast, 2020-2025

6.3.1 Sanger Sequencing

6.3.2 Pyrosequencing

6.3.3 Next-Generation Sequencing

6.3.4 Others

6.4 Polymerase Chain Reaction

Market Estimates & Forecast, 2020-2025

6.5 Others

Chapter 7. Global Pharmacogenomics Market, by Application

7.1 Introduction

7.2 Oncology

Market Estimates & Forecast, 2020-2025

7.2.1 Breast Cancer

7.2.2 Lung Cancer

7.2.3 Others

7.3 Cardiology

Market Estimates & Forecast, 2020-2025

7.4 Neurological Disorders

Market Estimates & Forecast, 2020-2025

7.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 8 Global Pharmacogenomics Market, by End User

8.1 Introduction

8.2 Hospitals and clinics

Market Estimates & Forecast, 2020-2025

8.3 Research Organizations

Market Estimates & Forecast, 2020-2025

8.4 Academic Institute

Market Estimates & Forecast, 2020-2025

8.5 Others

Market Estimates & Forecast, 2020-2025

Chapter 9. Global Pharmacogenomics Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape: Pharmacogenomics Market

10.1 Introduction

10.2 Pharmacogenomics Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Myriad Genetics, Inc.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 23andMe, Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pathway Genomics

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GeneTech

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 GeneDx.

11.5.1 Overview

11.5.2 Company Overview

11.5.3 Product Overview

11.5.4 Financial overview

11.5.5 Key Developments

11.6 Future Science Group

11.6.1 Overview

11.6.2 Company Overview

11.6.3 Product Overview

11.6.4 Financial Overview

11.6.5 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Assurex Health, Inc.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEOโ€™s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Pharmacogenomics Industry Synopsis, 2020-2025

Table 2 Global Pharmacogenomics Market Estimates and Forecast, 2020-2025, (USD Million)

Table 3 Global Pharmacogenomics Market by Region, 2020-2025, (USD Million)

Table 4 Global Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 5 Global Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 6 Global Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 7 North America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 8 North America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 9 North America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 10 US Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 11 US Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 12 US Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 13 Canada Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 14 Canada Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 15 Canada Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 16 South America Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 17 South America Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 18 South America Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 19 Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 20 Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 21 Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 22 Western Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 23 Western Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 24 Western Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 25 Eastern Europe Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 26 Eastern Europe Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 27 Eastern Europe Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 28 Asia Pacific Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 29 Asia Pacific Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 30 Asia Pacific Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

Table 31 Middle East & Africa Pharmacogenomics Market by Technology, 2020-2025, (USD Million)

Table 32 Middle East & Africa Pharmacogenomics Market by Application, 2020-2025, (USD Million)

Table 33 Middle East & Africa Pharmacogenomics Market by End Users, 2020-2025, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Pharmacogenomics Market

Figure 3 Segmentation Market Dynamics for Global Pharmacogenomics Market

Figure 4 Global Pharmacogenomics Market Share, by Technology 2020

Figure 5 Global Pharmacogenomics Market Share, by Application 2020

Figure 6 Global Pharmacogenomics Market Share, by End Users, 2020

Figure 7 Global Pharmacogenomics Market Share, by Region, 2020

Figure 8 North America Pharmacogenomics Market Share, by Country, 2020

Figure 9 Europe Pharmacogenomics Market Share, by Country, 2020

Figure 10 Asia Pacific Pharmacogenomics Market Share, by Country, 2020

Figure 11 Middle East & Africa Pharmacogenomics Market Share, by Country, 2020

Figure 12 Global Pharmacogenomics Market: Company Share Analysis, 2020 (%)

Figure 14 Myriad Genetics, Inc.: Key Financials

Figure 15 Myriad Genetics, Inc.: Segmental Revenue

Figure 16 Myriad Genetics, Inc.: Geographical Revenue

Figure 17 23andMe, Inc.: Key Financials

Figure 18 23andMe, Inc.: Segmental Revenue

Figure 19 23andMe, Inc.: Geographical Revenue

Figure 20 Pathway Genomics: Key Financials

Figure 21 Pathway Genomics: Segmental Revenue

Figure 22 Pathway Genomics: Geographical Revenue

Figure 23 GeneTech: Key Financials

Figure 24 GeneTech: Segmental Revenue

Figure 25 GeneTech: Geographical Revenue

Figure 26 GeneDx. : Key Financials

Figure 27 GeneDx. : Segmental Revenue

Figure 28 GeneDx. : Geographical Revenue

Figure 29 Future Science Group: Key Financials

Figure 30 Future Science Group: Segmental Revenue

Figure 31 Future Science Group: Geographical Revenue

Figure 32 Teva Pharmaceutical Industries Ltd.: Key Financial

Figure 33 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 34 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 35 Assurex Health, Inc..: Key Financials

Figure 36 Assurex Health, Inc.: Segmental Revenue

Figure 37 Assurex Health, Inc.: Geographical Revenue

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.